Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.30 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.30 |
| ▸ | INPP5B | P32019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239278 | 0.91 | FDPS (0.50) | FDPSBLMTDP1INPP5A | |
| SCHEMBL6856973 | 0.88 | FDPS (0.47) | FDPSBLMTDP1BTN3A1 | |
| SCHEMBL11402357 | 0.86 | FDPS (0.45) | FDPSBLMTDP1 | |
| SCHEMBL13183948 | 0.82 | FDPS (0.41) | FDPSBLMTDP1BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL28447258 | 0.81 | FDPS (0.77) | FDPSBLMTDP1INPP5ACA4 | |
| Hydrochloric Acid SCHEMBL7749523 | 0.80 | FDPS (0.45) | FDPSBLMTDP1BTN3A1 | |
| SCHEMBL333911 | 0.79 | — | — | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.76 | — | — | |
| Pyrophosphoric Acid SCHEMBL8851914 | 0.76 | FDPS (1.00) | FDPSBLMTDP1INPP5ACA4 | |
| Pyrophosphoric Acid SCHEMBL292348 | 0.76 | FDPS (1.00) | FDPSBLMTDP1INPP5ACA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260060989-A1 | Charged Ion Channel Blockers And Methods For Use | NOCION THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250263374-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250263386-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12303496-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-0672193-B1 | USE OF OLIGONUCLEOTIDES HAVING A CONSERVED G 4 CORE SEQUENCE FOR THE PREPARATION OF A MEDICAMENT | ISIS PHARMACEUTICALS INC (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6348312-B1 | OLIGONUCLEOTIDE HAVING LENGTH OF 6-100 NUCLEOTIDES, WHEREIN AT LEAST ONE NON-TERMINAL PYRIMIDINE NUCLEOSIDE IS MODIFIED, AND ALSO 5' AND/OR 3' ENDS ARE MODIFIED, BY REPLACEMENT OF 3' AND/OR 5' PHOSPHODIESTER BRIDGE BY PHOSPHOROTHIOATE BRIDGE | HOESCHT AKTIENGESELLSCHAFT (DE) | 2002-02-19 | — | — | US | disclosed |
| US-6339068-B1 | DETERMINING CPG-N AND CPG-S MOTIFS PRESENT IN NUCLEIC ACID CONSTRUCT COMPRISING AT LEAST ONE CPG-S MOTIF AND NUCLEIC ACID ENCODING ANTIGEN; REMOVING CPG-N MOTIFS FROM NUCLEIC ACID CONSTRUCT; INSERTING CPG-S MOTIFS INTO NUCLEIC ACID CONSTRUCT | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-01-15 | — | — | US | disclosed |
| EP-1016715-A1 | Oligonucleotides having a conserved G4 core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0942757-A2 | RADIOLABELED DNA OLIGONUCLEOTIDE, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF | Angiogene, Inc. (CA) | 1999-09-22 | — | — | EP | disclosed |
| US-5952490-A | A CHEMICALLY MODIFIED OLIGONUCLEOTIDE THAT INHIBITS VIRAL ACTIVITY OR PHOSPHOLIPASE A; TREATMENT OF AGING AND MALIGNANT CELL GROWTH | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5821354-A | SYNTHESIZING A DNA SEQUENCE IN AT LEAST TWO PARTS; LABELING THE 5' END OF ONE WITH A RADIOISOTOPE; HYBRIDIZING; LIGATING; USEFUL TO PREVENT UNCONTROLLED CELLULAR PROLIFERATION | ANGIOGENE INC. (CA) | 1998-10-13 | — | — | US | disclosed |
| WO-1998023299-A2 | RADIOLABELED DNA OLIGONUCLEOTIDE, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF | ANGIOGENE INC. (CA) | 1998-06-04 | — | — | WO | disclosed |
| US-5523389-A | OLIGONUCLEOTIDE WITH AT LEAST ONE LINKAGE OF PHOSPHOROTHIOATE | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-04 | — | — | US | disclosed |
| WO-1992001673-A1 | SYNTHESIS AND USES OF SPIN LABELLED RIBONUCLEOSIDES AND RIBONUCLEOTIDES | MEDICAL RESEARCH COUNCIL (GB) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | FDPS 611/4885BLM 1164/4885TDP1 201/4885 |
| US-12303496-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | FDPS 2654/4885BLM 2975/4885TDP1 4517/4885 |
| US-20250263386-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV5, TRPV2 | FDPS 3336/4885BLM 2856/4885TDP1 3447/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | FDPS 611/4885BLM 1164/4885TDP1 201/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | FDPS 3052/4885BLM 3764/4885TDP1 4216/4885 |
| US-20260060989-A1 | Charged Ion Channel Blockers And Methods For Use | TRPV1, TRPA1, TRPV2 | FDPS 4252/4885BLM 3525/4885TDP1 2590/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | FDPS 3621/4885BLM 2298/4885TDP1 4601/4885 |
| US-20250263374-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | FDPS 3052/4885BLM 3764/4885TDP1 4216/4885 |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | TRPV1, TRPA1, TRPV2 | FDPS 1734/4885BLM 4244/4885TDP1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.